This Is MS Multiple Sclerosis Knowledge & Support Community

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced that Trophos and partners in the MS-Repair consortium delivered an oral presentation detailing Trophos' novel approach in multiple sclerosis (MS) at the recent Society for Neuroscience (SfN) Meeting. The data presented demonstrate that olesoxime, Trophos' lead compound, is a promising candidate for neuroaxonal repair and remyelination in white matter diseases, notably multiple sclerosis. The MS-Repair project is supported by the French Agence Nationale pour la Recherche (ANR).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397

Oh, this is good news. In a long term perspective sort of way.

By the way, it needs an accent over the 'e,' It should be Olésoxime.